Navigating the Fas lane to improved cellular therapy for cancer.
Level V
Where this comes from
- Record sourced from PubMed, PMID 30830880.
- Also identified by DOI 10.1172/JCI127581 and PMC identifier 6436865.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Genetically engineered T cells have shown promising activity in the treatment of cancer. However, these cells are also potentially susceptible to immune-suppressive pathways in the tumor microenvironment that may limit their efficacy. In this issue of the JCI, Yamamoto et al. describe a new cellular engineering approach to prevent Fas-mediated inhibition of T cell function, which may be exploited to improve cellular therapy for cancer.
Medical subject headings
- Immunotherapy, Adoptive
- Neoplasms